{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Angina pectoris"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Atrial fibrillation"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Atrioventricular block first degree"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Bundle branch block left"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Left ventricular dysfunction"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Palpitations"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Pericardial effusion"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Sinus bradycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}],"title":"Sinus tachycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Supraventricular tachycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Tachycardia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Ventricular arrhythmia"}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"}],"units":"Participants"}],"description":"An abnormal ECG findings that were judged by the investigator to be medically significant were reported as AEs. The TEAEs are defined as AEs present at baseline that worsened in intensity after administration of study drug, or events absent at baseline that emerged after administration of study drug, up to 30 days after the last dose of study drug (approximately 7 months).","groups":[{"description":"Participants received intravenous infusion of moxetumomab pasudotox 40 µg/kg on Days 1, 3, and 5 of each 28-day cycle for up to 6 cycles, until documentation of complete response, progressive disease, initiation of alternate therapy, or unacceptable toxicity.","id":"OG000","title":"Moxetumomab Pasudotox 40 µg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety population included participants who received at least 1 dose of moxetumomab pasudotox.","reportingStatus":"POSTED","timeFrame":"From the start of study treatment (Day 1) through 4-6 weeks after last dose of Cycle 6 (28-day cycle) (approximately 7 months)","title":"Number of Participants With Abnormal Electrocardiogram (ECG) Reported as TEAEs","type":"SECONDARY","unitOfMeasure":"Participants"}